7 Oct 2022 13:16
PDMR Dealing Amendment
Â
The following amendment has been made to the ('PDMR Dealing') announcement released on 7 October 2022 at 12:28pm under RNS No 2105C
 Â
Amendments are identified with an asterisk (*).
Â
Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.006%* of the Company.
Â
All other details remain unchanged.
Â
The full amended text is shown below.
Â
Oxford, UK - 7 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group, was informed that Matthew Treagus, Chief Information Officer, has purchased 1,390 ordinary shares of 50p each ("Ordinary Shares") in the Company on 7 October 2022 on the London Stock Exchange at a price of 355.6655p. Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.006%* of the Company.
Â
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
Â
Â
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Matthew Treagus | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Information Officer  | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument  Identification code | Ordinary Shares of 50 pence each   ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase | ||||
c) | Price(s) and volumes(s) | Â
| ||||
d) | Aggregated information · Aggregated volume · Aggregated total  |  1,390  £4,943.75  | ||||
e) | Date of the transaction | 07-10-2022 | ||||
f) | Place of the transaction | London Stock Exchange, Main Market (XLON) |
Â
Â
Â
-Ends-
Â
For further information, please contact: | |
 Oxford Biomedica plc: Natalie Walter, Company Secretary |  Tel: +44 (0)1865 783 000 |
Â
Â
About Oxford Biomedica
Â
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Â
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.
Â
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Â
Further information is available at www.oxb.com.
Â